Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Finance Watch: Have Biopharma IPOs Hit Their Limit?

Nov 18 2020

• By Mandy Jackson, Anju Ghangurde, and Kevin Grogan

Finance Watch

Related Content

Keeping Track: Disappointment For Mesoblast And Aquestive; Opdivo/Yervoy Add Mesothelioma Claim; Pediatric Approvals

Oct 03 2020

Biocon Biologics Receives Further Investment As Value Hits $3.5bn

Jul 31 2020

1ST Bio Bets On BBB-Penetrating C-ABL Inhibitor As Potential Disease-Modifying Parkinson's Drug

Jun 01 2018

Keeping Track: Keytruda Claims First TMB-Based Cancer Indication; TG Therapeutics Submits First Umbralisib NDA

Jun 22 2020

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

Apr 03 2018

Finance Watch: As US IPO Market Gets More Challenging, Two Companies Opt Out

Nov 13 2019

Biocon Rings In 2020 With Gusto, PE Investment In Biologics Arm

Jan 07 2020

China Cell Therapy Party On: $500m+ Raised In JW IPO, Other Rounds

Nov 06 2020

Finance Watch: Joe Jimenez Ventures Into Start-Up World Via Aditum

Nov 03 2020

Five Prime Lands Blow On Gastric Cancers With FGFR2b Antibody

Nov 11 2020

Kinnate Raises $98m To Take Kinase Inhibitors Into The Clinic

Aug 26 2020

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Jun 06 2020

Finance Watch: ORIC Raises $120m In Another Pandemic Era Biopharma IPO

Apr 25 2020

Finance Watch: iTeos, Pandion And Aspen Show COVID-19 Hasn’t Slowed VC Deals Yet

Apr 01 2020

IPO Update: Biopharma Stands Out Among Gloomy US Market

Apr 16 2020

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

May 24 2020

Destiny And SporeGen Back Nasal Spray Over Vaccine To Tackle COVID-19

Sep 09 2020

Biocon Sees Recovery In Biosimilars, Scope To Address Affordability In US

Jul 27 2020

Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising

Jul 03 2020

Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments

Jul 15 2020

Chi-Med Extends Oncology Commercial Reach To Realize China Potential

Jul 31 2020

BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten

Oct 05 2020

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

Oct 06 2020

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Oct 02 2020

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Oct 26 2020

Finance Watch: Coronavirus-Related Stock Market Meltdown Didn’t Stop Passage Bio IPO

Mar 03 2020

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

Oct 10 2019

Viatris Plots ‘Significant’ Restructuring As Mylan-Upjohn Merger Completes

Nov 16 2020

Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development

Apr 23 2018

Related Companies

IN8bio, Inc.

Inhibikase Therapeutics, Inc.

Compass Therapeutics Inc.

Royalty Pharma plc

Lantern Pharma, Inc

Poseida Therapeutics, Inc.

COMPASS Pathways

1ST Biotherapeutics, Inc.

Olema Pharmaceuticals, Inc.

BioAtla, Inc.

Sigilon Therapeutics, Inc.

Atea Pharmaceuticals, Inc.

Galecto Inc.

SQZ Biotechnologies Company

JW Therapeutics Co., Ltd

Biocon, Ltd.

Roche Holding AG

Syngene International Ltd.

Viatris Inc.

Pfizer Inc.

Additional Topics

Financing Business Strategies Growth Innovation Commercial BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window